RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute. We discussed:The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients.The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib.The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors.Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice.The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients. Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:⁠X/Twitter: https://twitter.com/oncbrothers⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/ Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment!#PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers